cardiac monitor that contiusly monity st elevation

#Cardiac monitor that contiusly monity st elevation software

7,8 Treatment decisions for NSTEMI/UA are based largely on symptoms and resting or exercise electrocardiograms (ECG). 6 Among the three types, NSTEMI/UA is nearly four times as common as STEMI. There are three types of ACS: ST elevation myocardial infarction (STEMI), non-ST elevation MI (NSTEMI), and unstable angina (UA). However, there is considerable debate among clinicians, about which treatment pathway is best: early invasive using percutaneous coronary intervention (PCI/stent) when indicated or a conservative approach ( i.e., medications only or PCI/stent if recurrent symptoms occur). 1 The pathophysiology of ACS involves rupture of an atherosclerotic plaque hence, treatment is aimed at plaque stabilization in order to prevent cellular death. The purpose of this manuscript is to describe the ECG application and analysis methodology used in the COMPARE Study (electro Cardiographic evaluati On of ische Mia com Paring inv Asive to pha Rmacological tr Eatment (R21 NR-011202), which might be utilized by other researches exploring this clinical problem.Įach year, nearly 700,000 Americans will have a new coronary attack, or acute coronary syndrome (ACS). Because of the prevalence of CAD, clinicians working in hospitals are likely to encounter these patients frequently. 1 More than half of the hospital stays for CAD were among patients who also received percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) during their stay.

#Cardiac monitor that contiusly monity st elevation software

Off-line ECG analysis is done using sophisticated software and careful human oversight.Īccording to the most recent American Heart Association statistics, coronary artery disease (CAD) was estimated to be responsible for 1.2 million hospital stays and was the most expensive medical condition treated. Patients are also maintained on the routine bedside ECG monitoring system per hospital protocol. Once consented, a 12-lead ECG Holter monitor is applied, and remains in place during the patient's entire hospital stay. Research nurses identify hospitalized patients from the emergency department and telemetry unit with suspected ACS. Permission to proceed with this study was obtained from the Institutional Review Board of the hospital and the university. The purpose of this manuscript is to describe the methodology used in the COMPARE Study. Therefore, using 12-lead ECG monitoring, the COMPARE Study (electro Cardiographic evaluati On of ische Mia com Paring inv Asive to pha Rmacological tr Eatment) was designed to assess the frequency and clinical consequences of transient myocardial ischemia, in patients with NSTEMI/UA treated with either early invasive PCI/stent or those managed conservatively (medications or PCI/stent following recurrent symptoms). Information obtained with 12-lead ECG monitoring might provide useful information for deciding the best ACS treatment. However, continuous 12-lead ECG monitoring is not usual hospital practice rather, only two leads are typically monitored.

However, because of the dynamic and unpredictable nature of the atherosclerotic plaque, these methods often under detect myocardial ischemia because symptoms are unreliable, and/or continuous ECG monitoring was not utilized.Ĭontinuous 12-lead ECG monitoring, which is both inexpensive and non-invasive, can identify transient episodes of myocardial ischemia, a precursor to MI, even when asymptomatic. Treatment decisions for NSTEMI/UA are based largely on symptoms and resting or exercise electrocardiograms (ECG). Among the three types, NSTEMI/UA is nearly four times as common as STEMI. However, there is considerable debate among clinicians, about which treatment pathway is best: early invasive using percutaneous coronary intervention (PCI/stent) when indicated or a conservative approach ( i.e., medication only with PCI/stent if recurrent symptoms occur). The pathophysiology of ACS involves rupture of an atherosclerotic plaque hence, treatment is aimed at plaque stabilization in order to prevent cellular death. Each year, an estimated 785,000 Americans will have a new coronary attack, or acute coronary syndrome (ACS).